Development of a P1 phagemid system for the delivery of DNA into Gram-negative bacteria

Microbiology
C WestwaterJ W Dolan

Abstract

The inability to transform many clinically important Gram-negative bacteria has hampered genetic studies addressing the mechanism of bacterial pathogenesis. This report describes the development and construction of a delivery system utilizing the broad-host-range transducing bacteriophage P1. The phagemids used in this system contain a P1 pac initiation site to package the vector, a P1 lytic replicon to generate concatemeric DNA, a broad-host-range origin of replication and an antibiotic-resistance determinant to select bacterial clones containing the recircularized phagemid. Phagemid DNA was successfully introduced by infection and stably maintained in members of the families Enterobacteriaceae (Escherichia coli, Shigella flexneri, Shigella dysenteriae, Klebsiella pneumoniae and Citrobacter freundii) and Pseudomonadaceae (Pseudomonas aeruginosa). In addition to laboratory strains, these virions were used successfully to deliver phagemids to a number of strains isolated from patients. This ability to deliver genetic information to wild-type strains raises the potential for use in antimicrobial therapies and DNA vaccine development.

References

Jun 1, 1992·Applied and Environmental Microbiology·O A OgunseitanR V Miller
Jan 1, 1991·Methods in Enzymology·D HanahanF R Bloom
Aug 15, 1990·Analytical Biochemistry·J M DiverP A Sokol
May 17, 1990·Nature·F YamamotoS Hakomori
May 1, 1990·Canadian Journal of Microbiology·T ShireenZ U Ahmed
Jan 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·N Sternberg
Aug 1, 1989·Molecular & General Genetics : MGG·M J Benedik
Jul 11, 1988·Nucleic Acids Research·W J DowerC W Ragsdale
Jul 1, 1988·Applied and Environmental Microbiology·L R ZephG Stotzky
Apr 1, 1972·Journal of Virology·W D Lawton, D M Molnar
Apr 13, 1968·Nature·M Okada, T Watanabe
Mar 1, 1970·Journal of Bacteriology·G S Omenn, J Friedman
Aug 25, 1981·Journal of Molecular Biology·N Sternberg, D Hamilton
Dec 1, 1995·Molecular Biotechnology·P K Dinsmore, T R Klaenhammer
Feb 1, 1997·Canadian Journal of Microbiology·C G Gliesche
Jan 7, 1998·Scientific American·R V Miller
Feb 18, 1999·JAMA : the Journal of the American Medical Association·J WienerR A Weinstein
Mar 3, 1999·JAMA : the Journal of the American Medical Association·K GuptaW E Stamm
May 29, 1999·Antimicrobial Agents and Chemotherapy·R E Hancock, D S Chapple
Dec 22, 1999·European Journal of Immunology·A W ZuercherB M Stadler

❮ Previous
Next ❯

Citations

Nov 20, 2014·ACS Synthetic Biology·Weiyue JiWendell A Lim
Oct 16, 2015·Biotechnology and Bioengineering·Michelle L LuoChase L Beisel
Dec 13, 2019·Scientific Reports·Carola VenturiniSteven P Djordjevic
Feb 19, 2021·MSphere·Chelsea M KellerMauricio H Pontes
May 10, 2013·ACS Synthetic Biology·Joshua T KittlesonJ Christopher Anderson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.